MarketBeat
09 May 2026, 06:10 UTC · 23w ago
Verdict
Headline takes no side. We score VCEL +1.00 across five claims — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
Scored by the NIS engine · methodology.
What the story claims
5 claims · scored −1 bearish … +1 bullish
Vericel raised its full-year 2026 total revenue guidance by $10 million to $326M-$336M and significantly raised its Burn Care revenue outlook to $44M-$48M from $36M.
So whatRaising top-line guidance—particularly the nearly 25% bump in Burn Care expectations—directly increases forward earnings estimates and signals stronger than previously communicated demand.
More positive than 99% of claims this week
Vericel secured a BARDA award valued at up to $197 million for NexoBrid, with management expecting approximately two-thirds of the value to flow to the company and $5M-$6M in procurement revenue starting in H2 2026.
Continue reading
5 related stories
Top 2 movers · tap to explore
So whatA large, multi-year federal contract provides highly visible, high-margin revenue streams for NexoBrid and materially de-ramps the commercialization trajectory of the product.
More positive than 99% of claims this week
Total Q1 revenue rose 30% year over year to $68.4 million, significantly beating the company's guidance range, alongside a 195% surge in adjusted EBITDA to $9.6 million and a 300+ basis point gross margin expansion.
So whatA significant top-line beat combined with substantial operating leverage and margin expansion demonstrates improving profitability and validates the company's growth trajectory.
More positive than 98% of claims this week
Vericel's expanded MACI sales force achieved record Q1 biopsies and implanting surgeons with zero disruption, driving accelerating implant growth in both new and legacy territories.
More positive than 98% of claims this week
Early clinical data for MACI Arthro suggests reduced post-surgical pain and faster recovery, with peer-reviewed publication accepted, and trained surgeons already account for over half of MACI implants.
More positive than 90% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company reported record first-quarter revenue, raised its full-year 2026 outlook, and showed strong growth across all key financial measures and product lines.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
27m ago
+22.4%
Price agrees with the score
$40.94 vs $33.46 close before publication (May 8) · not market-adjusted
VCEL chart →
